LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Akcijų sąrašas・Geron Corp

Geron Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

1.29 -7.86

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.28

Max

1.32

Pagrindiniai rodikliai
By Trading Economics
Pajamos	25M -3.6M
Pardavimai	3.8M 52M
Pelnas, tenkantis vienai akcijai	-0.005
Pelno marža	-7.026
Darbuotojai	258
EBITDA	24M 90K

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+151.94% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-114M 892M
Ankstesnė atidarymo kaina	9.15
Ankstesnė uždarymo kaina	1.29

Naujienos nuotaikos

By Acuity

65%

35%

285 / 345 reitingas Healthcare

Geron Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-15 22:47; UTC

Karštos akcijos

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

2026-05-15 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

2026-05-15 22:00; UTC

Pagrindinės rinkos jėgos

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

2026-05-15 18:09; UTC

Pagrindinės rinkos jėgos

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

2026-05-15 16:02; UTC

Uždarbis

Pagrindinės rinkos jėgos

Forward Industries Shares Fall on New Debt as Solana Value Drops

2026-05-15 14:55; UTC

Pagrindinės rinkos jėgos

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

2026-05-16 16:27; UTC

Įsigijimai, susijungimai, perėmimai

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

2026-05-16 08:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

2026-05-15 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

2026-05-15 21:16; UTC

Rinkos pokalbiai

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 20:19; UTC

Karštos akcijos

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

2026-05-15 19:41; UTC

Įsigijimai, susijungimai, perėmimai

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

2026-05-15 19:35; UTC

Rinkos pokalbiai

Oil Futures Settle Higher on Inventory Worries -- Market Talk

2026-05-15 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

2026-05-15 18:35; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

2026-05-15 17:28; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

2026-05-15 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

2026-05-15 16:24; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

2026-05-15 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-15 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 15:55; UTC

Rinkos pokalbiai

Canada's 1Q Rebound Not a Turning Point -- Market Talk

2026-05-15 15:20; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-15 15:20; UTC

Rinkos pokalbiai

Silver Plunges on Inflation Worries -- Market Talk

2026-05-15 15:20; UTC

Uždarbis

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Geron Corp Prognozė

Kainos tikslas

By TipRanks

151.94% į viršų

12 mėnesių prognozė

Vidutinis 3.25 USD 151.94%

Aukščiausias 5 USD

Žemiausias 1 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Geron Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Geron Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

285 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.